Translating psoriasis guidelines into practice: Important gaps revealed - 16/02/16
, Mark G. Lebwohl, MD b, Alice B. Gottlieb, MD, PhD c, Kevin Boyer, MPH a, Elaine Hamarstrom, PhD a, Neil J. Korman, MD, PhD d, Robert S. Kirsner, MD, PhD e, Arthur J. Sober, MD f, Alan Menter, MD gAbstract |
Background |
There is a well-established lack of adherence to evidence-based clinical guidelines. The American Academy of Dermatology (AAD) developed educational sessions entitled Translating Evidence into Practice based on the published guidelines for psoriasis and psoriatic arthritis.
Objective |
We sought to determine the effectiveness of Translating Evidence into Practice sessions in improving patient care.
Methods |
Pre- and post-session surveys were administered at Translating Evidence into Practice sessions. A follow-up was administered 6 months after completion of the most recent session, which was 2.5 years after the first session.
Results |
At both post-session and follow-up, more than 92% of participants believed the sessions had improved their knowledge. The proportion of participants that self-reported assessing disease severity, comorbidities, and quality of life increased at follow-up. Participants' self-reported counseling of patients and confidence in treating psoriasis and psoriatic arthritis also increased at post-session and follow-up. Greater than 97% of participants thought the sessions would have a positive impact on their practice whereas 50% reported making a change in practice.
Limitations |
Lack of a control group, the self-reported nature of the data, and potential participant bias are limitations.
Conclusion |
The AAD's Translating Evidence into Practice sessions are effective and well received for improving knowledge and practice and can be useful to determine self-reported practice gaps.
Il testo completo di questo articolo è disponibile in PDF.Key words : assessment of severity, cardiovascular disease, guidelines, metabolic syndrome, practice gaps, psoriasis, psoriatic arthritis, quality of life
Abbreviations used : AAD, PsA, QOL
Mappa
| Funding sources: None. |
|
| Disclosure: Dr Lebwohl is an employee of the Mount Sinai Medical Center, which receives research funds from AbGenomics, AbbVie, Amgen, Anacor, Aqua, Canfite Biopharma, Celgene, Clinuvel, Coronado Biosciences, Ferndale, Eli Lilly and Company, Janssen Biotech, LEO Pharmaceuticals, Merz, Novartis, Pfizer, Sandoz, Sun Pharmaceuticals, and Valeant. Dr Gottlieb maintains current consulting/advisory board agreements with Amgen Inc, Astellas, Akros, Centocor (Janssen), Celgene Corp, Bristol Meyers Squibb Co, Beiersdorf Inc, Abbott Labs (Abbvie), TEVA, Actelion, UCB, Novo Nordish, Novartis, Dermipsor Ltd, Incyte, Pfizer, Canfite, Eli Lilly and Company, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Life, Glaxo Smith Kline, Xenoport, Catabasis, Mriji Seika Pharma Co Ltd, Takeda, Mitsubishi, and Tanabe Pharma Development America Inc, Genentech. Dr Korman has served on advisory boards or as a speaker for Abbvie, Amgen, Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuticals Inc, Novartis Pharmaceuticals Corp, and Pfizer Inc. Dr Menter served as consultant or investigator for Abbott Laboratories, receiving honoraria; served on advisory boards or as a speaker for Abbott Laboratories, AbbVie, Amgen, Astellas Pharma US Inc, Centocor Ortho Biotech Inc, Galderma Laboratories LP, Pfizer Inc, and Warner Chilcott, receiving honoraria or fees; and had or has pending grants from Amgen, Celgene Corporation, Centocor Ortho Biotech Inc, and Pfizer Inc. Drs Bhushan, Hamarstrom, Kirsner, and Sober, and Mr Boyer have no conflicts of interest to declare. |
Vol 74 - N° 3
P. 544-551 - marzo 2016 Ritorno al numero
Articolo precedente
- Morphological and immunohistochemical clues for the diagnosis of cutaneous leishmaniasis and the interpretation of CD1a status
- Angel Fernandez-Flores, José Luis Rodriguez-Peralto
- Intralesional 5-fluorouracil (FU) as a treatment for nonmelanoma skin cancer (NMSC): A review
- Lauren Metterle, Christopher Nelson, Nishit Patel
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?